TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) just unveiled an announcement.
BioDlink International Company Limited reported a 6% decrease in operating revenue for the first half of 2025, attributed to intensified competition and delayed project milestones. Despite a significant 87% drop in net profit, the company expanded its international presence with Bevacizumab injection approvals in Nigeria and Pakistan, and GMP inspections passed in several countries. The company also authorized Zhaoke Ophthalmology Limited as the marketing authorization holder for TAB014 in China, marking a strategic move in the ophthalmic drug market.
The most recent analyst rating on (HK:1875) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited, incorporated in Hong Kong, operates in the biopharmaceutical industry. The company focuses on the development and commercialization of pharmaceutical products, with a particular emphasis on Bevacizumab injection, marketed in China as Pusintin®, and TAB014 for treating wet age-related macular degeneration (wAMD).
Average Trading Volume: 259,830
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.99B
For a thorough assessment of 1875 stock, go to TipRanks’ Stock Analysis page.